Artbio, a radiopharmaceutical company developing a new class of targeted alpha radioligand therapies (ARTs), has named ...

Chinese metabolic diseases specialist Hangzhou Sciwind Biosciences has announced details of a deal with Verdiva Bio for the ...

Mountainfield Venture Partners and Keymed Biosciences launch Timberlyne Therapeutics with $180 million in series A funding.

US biopharma Vertex Pharmaceuticals has entered an exclusive collaboration and license agreement with China’s Zai Lab for the ...

US pharma giant Pfizer today announced positive top-line results from its pivotal Phase III CREST trial evaluating sasanlimab ...

USA-based Light Horse Therapeutics has been established as a new small molecule therapeutics developer, with a $62 million ...

Intellia Therapeutics, a US gene editing company developing CRISPR-based therapies, announced late Thursday its strategic ...

German biotech CatalYm has appointed Scott Clarke as chief executive (CEO), noting that he brings over two decades of ...

The type 1 diabetes (T1D) market across the seven major markets (7MM: USA, France, Germany, Italy, Spain, the UK, and Japan) ...

Pfizer ends its collaboration with Sangamo Therapeutics on a haemophilia A gene therapy despite strong Phase III results and ...

Kazia Therapeutics faces a setback as the FDA deems accelerated approval for brain cancer drug paxalisib unlikely despite ...

California-based IDEAYA Biosciences has entered into an exclusive license agreement for SHR-4849, a novel DLL3-targeting Topo ...